

Cover Story
Conversation with The Cancer Letter
On Dec. 3, the faculty and staff members at the OHSU Knight Cancer Institute received an email from Brian J. Druker, the institution’s star scientist, former director, and current CEO, informing them that he would be stepping down from his executive role.
By Yiqing Wang
In Brief


Clinical Roundup
Drugs & Targets


NCI Trials


NCI Trials for December 2024
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Trump et al. focus on NIH, cancer—and how peer review is done
- Bhattacharya provides calm answers to anxious questions at confirmation hearing
Trump nominee for NIH director calls for transparency, audits of indirect costs - Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills - In the Headlines: What are Jay Bhattacharya’s plans for NIH?
- Harnessing innovation: The next frontier in surgical oncology
- Biden’s FY23 proposal cuts NCI funds by $199M, while boosting ARPA-H by $4B